This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental material
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Prey, J.
Right arrow Articles by Ryan, K. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Prey, J.
Right arrow Articles by Ryan, K. M.

 Previous Article  |  Next Article 

Journal of Virology, June 2008, p. 5933-5939, Vol. 82, No. 12
0022-538X/08/$08.00+0     doi:10.1128/JVI.02273-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Tumor Antigen LRRC15 Impedes Adenoviral Infection: Implications for Virus-Based Cancer Therapy{triangledown} ,{dagger}

Jim O'Prey,1,{ddagger} Simon Wilkinson,1,{ddagger} and Kevin M. Ryan1,2*

Tumour Cell Death Laboratory, Beatson Institute for Cancer Research, Garscube Estate, Switchback Road, Glasgow G61 1BD,1 Glasgow Centre for Cancer Research, University of Glasgow, Glasgow G12 8QQ, United Kingdom2

Received 19 October 2007/ Accepted 24 March 2008

Adenoviruses for gene or oncolytic therapy are under development. Notable among these strategies is adenoviral delivery of the tumor suppressor p53. Since all therapeutics have limitations in certain settings, we have undertaken retroviral suppressor screens to identify genes conferring resistance to adenovirus-delivered p53. These studies identified the tumor antigen LRRC15, which is frequently overexpressed in multiple tumor types, as a repressor of cell death due to adenoviral p53. LRRC15, however, does not impede p53 function per se but impedes adenoviral infection. Specifically, LRRC15 causes redistribution of the coxsackievirus-adenovirus receptor away from the cell surface. This effect is manifested in less adenoviral binding to the surfaces of LRRC15-expressing cells. This discovery, therefore, not only is important for understanding adenoviral biology but also has potentially important implications for adenovirus-based anticancer therapeutics.

* Corresponding author. Mailing address: Beatson Institute for Cancer Research, Garscube Estate, Switchback Road, Glasgow G61 1BD, United Kingdom. Phone: 441413303655. Fax: 441419426521. E-mail: k.ryan{at}beatson.gla.ac.uk

{triangledown} Published ahead of print on 2 April 2008.

{dagger} Supplemental material for this article may be found at http://jvi.asm.org/.

{ddagger} J. O'Prey and S. Wilkinson contributed equally to this work.

Journal of Virology, June 2008, p. 5933-5939, Vol. 82, No. 12
0022-538X/08/$08.00+0     doi:10.1128/JVI.02273-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»